Somatostatin Receptor Imaging in NPC, EBV Related Cancers

Study Overview
=================
Brief Summary
-----------------
The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.

Official Title
-----------------
Somatostatin Receptor Imaging in Nasopharyngeal Cancer, Epstein-Barr Virus (EBV) Related Cancers and Other Rare Tumors

Conditions
-----------------
Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma

Intervention / Treatment
-----------------
* Radiation: FDG-PET
* Radiation: Galium-68 DOTATATE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Locally advanced, metastatic or locally recurrent NPC that are going for FDG PET as part of their investigations Patients that have gone for Ga-68 DOTATATE imaging before are eligible for repeat imaging Histologically confirmed NPC Above 21 years of age Exclusion Criteria: Patients below 21 years of age Pregnant and breast feeding ladies

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: PET imaging<br> | Radiation: FDG-PET<br>* Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose. Scanning will be performed at an interval of at least 60 minutes following the injection.<br>Radiation: Galium-68 DOTATATE<br>* 200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of tracer uptake in the tumour lesions of NPC patients | The maximum standardized uptake values (SUVmax) will be measured. If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density. | From time of tracer injection to time the scan is performed | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of tracer uptake in the tumour lesions of patients with EBV related cancers | The maximum standardized uptake values (SUVmax) will be measured. If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density. | From time of tracer injection to time the scan is performed | 
| Number of somatostatin receptors in patient biopsy samples |  | Upon signing the informed consent form | 
| Amount of somatostatin circulating tumour cells in patient blood samples |  | At the time of scan | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Somatostatin, EBV, NPC, Rare Cancer